BR100 Decreased By (-0.91%)
BR30 Decreased By (-1.47%)
KSE100 Decreased By (-0.78%)
KSE30 Decreased By (-0.75%)
AGHA 6.70 Increased By ▲ 0.02 (0.3%)
BECO 4.37 No Change ▼ 0.00 (0%)
BML 56.00 Decreased By ▼ -1.32 (-2.3%)
BOP 30.09 Decreased By ▼ -0.26 (-0.86%)
CNERGY 12.95 Decreased By ▼ -0.17 (-1.3%)
CSIL 5.33 Decreased By ▼ -0.08 (-1.48%)
FCCL 51.50 Decreased By ▼ -1.29 (-2.44%)
FFL 14.47 Decreased By ▼ -0.25 (-1.7%)
FNEL 1.22 Increased By ▲ 0.10 (8.93%)
KEL 6.03 Decreased By ▼ -0.06 (-0.99%)
KOSM 5.84 Increased By ▲ 0.11 (1.92%)
LOTCHEM 26.20 Decreased By ▼ -0.26 (-0.98%)
MLCF 91.00 Decreased By ▼ -2.16 (-2.32%)
NBP 164.00 Decreased By ▼ -0.66 (-0.4%)
NCPL 53.00 Decreased By ▼ -2.66 (-4.78%)
NPL 59.40 Decreased By ▼ -1.76 (-2.88%)
OGDC 313.67 Decreased By ▼ -3.06 (-0.97%)
PACE 9.72 Decreased By ▼ -0.15 (-1.52%)
PAEL 35.27 Decreased By ▼ -0.36 (-1.01%)
PIBTL 14.71 Increased By ▲ 0.03 (0.2%)
PPL 221.18 Decreased By ▼ -5.73 (-2.53%)
PRL 90.91 Decreased By ▼ -2.11 (-2.27%)
PTC 58.53 Decreased By ▼ -1.73 (-2.87%)
SSGC 23.30 Decreased By ▼ -0.51 (-2.14%)
TBL 8.78 Increased By ▲ 0.03 (0.34%)
TELE 7.60 Decreased By ▼ -0.20 (-2.56%)
TPL 22.03 Decreased By ▼ -0.32 (-1.43%)
TPLP 12.60 Decreased By ▼ -0.37 (-2.85%)
TREET 21.77 Decreased By ▼ -0.39 (-1.76%)
TRG 55.91 Decreased By ▼ -0.65 (-1.15%)
By

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed for this article.